New CDC guidance says that Americans who live in areas with low to medium COVID-19 transmission can stop wearing masks indoors; GlaxoSmithKline (GSK) halts 3 vaccine clinical trials for the respiratory syncytial virus in pregnant women; a scientific advisory panel recommends a major overhaul of the US transplant system.
The CDC issued new guidance stating that most Americans, including students in schools, who live in areas where community transmission of COVID-19 is a low or medium threat to hospitals can safely remove their masks while indoors. The Associated Press reports that the new guidance will apply to more than 70% of the US population, whereas 37% of US counties are still deemed at high risk for the virus. The guidance does not change the requirement to wear masks on public transportation or indoors in airports, train stations, and bus stations.
Reuters reports that GlaxoSmithKline (GSK) halted enrollment and vaccination Monday in 3 trials investigating use of its experimental vaccine against the respiratory syncytial virus (RSV) in pregnant women. As the latest setback for the vaccine, the announcement comes after GSK had paused its late-stage trial, called GRACE, and 2 other studies on February 18 amid safety recommendations from an independent committee that has yet to provide further details. GSK’s RSV vaccine trial in adults aged 60 and over has not been halted, with the company adding that safety data from the maternal trials is still ongoing.
A report from the National Academies of Sciences, Engineering, and Medicine recommended that the US transplant system be overhauled in the next 5 years. The report highlighted flaws preventing the United States from performing more life-saving transplants. More than 106,000 patients are waiting for transplants; 17 die each day before they are able to undergo surgery. Many in need of a transplant are unable to be placed on waiting lists, whether because of geographic disparities or racial disparities.
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More